论文部分内容阅读
侵袭性真菌感染尤其是侵袭性曲霉病为ICU和血液系统肿瘤患者重要死因。伏立康唑具有广谱抗菌活性,现已成为侵袭性曲霉病的一线治疗药物。但是伏立康唑可导致多种不良反应,包括视觉障碍、中毒性脑病、肝酶升高等。伏立康唑具有非线性药动学特征并主要经肝脏由细胞色素P450酶系代谢,因此其代谢受年龄、基因等因素影响,而同时应用的其他药物也可能影响该药物的体内代谢。不同患者该药的药动学特点可有很大差异,从而影响临床疗效或导致毒性
Invasive fungal infections, especially invasive aspergillosis, are important causes of death in patients with ICU and hematological malignancies. Voriconazole has broad spectrum antibacterial activity and has now become the first-line treatment for invasive aspergillosis. But voriconazole can cause a variety of adverse reactions, including visual impairment, toxic encephalopathy, elevated liver enzymes. Voriconazole has nonlinear pharmacokinetic characteristics and is mainly metabolized by the liver by cytochrome P450 enzymes. Therefore, its metabolism is affected by age, gene and other factors, while other drugs used at the same time may also affect the in vivo metabolism of the drug. The pharmacokinetic characteristics of the drug may vary widely among patients and may have clinical effects or toxicity